fertiShare Evaluation

July 24, 2025 updated by: Sofia Gameiro, Cardiff University

Protocol for a Realist Evaluation and Feasibility RCT: Understanding and Developing a SPIKES-based eLearning Training Course Called fertiShare to Support Sharing Bad News Encounters Between Fertility Healthcare Professionals (FHPs) and Patients

Sharing bad news (SBN) is a daily challenge for fertility staff and patients. Bad news happens at all stages of fertility care and includes e.g., diagnosing infertility, reporting unexpected, repeated, or definitive treatment failure. Extensive evidence shows that SBN triggers stress in staff due to anticipation of negative emotions and evaluations or, in extreme cases, even complaints and lawsuits. Inability to manage bad news can increase negative emotions in patients and fuel distrust, potentially leading to treatment discontinuation. Efficient SBN training exists but does not address challenges of SBN in fertility care, does not meet fertility staff training and patient care preferences, and its impact on patients is unclear.

fertiShare is a brief, evidence-based, e-Learning SBN course bespoke for fertility care. The aim of the study is to evaluate the feasibility of implementing fertiShare at fertility clinics and of implementing an online multi-centre RCT to determine fertiShare's efficacy. This will allow to conclude if fertiShare should proceed to efficacy evaluation.

An international interdisciplinary stakeholder group (patients, consultants, embryologists, nurses, psychologists, digital educators) will inform all aspects of the proposed project.

Study Overview

Detailed Description

The aim of the feasibility study is to make a fully informed decision about whether fertiShare should proceed to efficacy evaluation. This aim will be achieved by resolving uncertainties about implementing fertiShare at fertility clinics and about running an online multi-centre efficacy RCT for fertiShare.

Design: Pre-registered, online, multi-centre, two-arm, triple-blinded (staff, patients, data analysts), feasibility RCT with 1:1 computer-generated randomized allocation to the intervention (fertiShare) or minimal SBN information control (20 mins SBN lecture emulating what most staff would receive as part of general training) groups.

The trial will include a process evaluation and adopt a pragmatic attitude to maximise the applicability of findings to fertility care practice (beyond the immediate trial setting). Examples of design choices that translate this pragmatic attitude are our choice of the control condition (emulating general SBN training that most staff will have), the inclusion of multiple staff and patient secondary trial outcomes (informed by stakeholders) and low standardisation of intervention delivery (staff will apply fertiShare as they think best). Criteria for progression to efficacy evaluation will be specified prior to implementation using a traffic-light system.

Setting: Six UK-based private and public fertility clinics.

Participants: Staff working at clinics whose role involves 10% of week time SBN. Exclusion criteria are being unable to undergo training.

Patient inclusion criteria are having received bad news from participating staff within last month. No exclusion criteria are applied.

Bad news is defined as any news meaning that patients' first or second complete (fresh and frozen embryo transfers) initiated In Vitro Fertilization cycle did not result in a clinical pregnancy, as this is the most common challenging bad news shared by staff, and to ensure that patient outcome data (specifically continuation data) are comparable.

Guidance for feasibility studies to estimate participation rates, based on review of evidence from RCTs conducted within SBN training and fertility care, indicates 75% of staff will be eligible and participate, but a conservative estimate of 50% will be considered to decrease unknown risk. Recruiting 60 staff (10 per clinic) will allow to calculate a 50% participation rate to 95%CI of ±11%. 52% of patients will be eligible and participate. Recruiting 180 patients per cohort (30 per clinic) will allow to calculate a 60% participation rate to 95%CI of ±6%.

Study Type

Interventional

Enrollment (Estimated)

420

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Aberdeen, United Kingdom, AB25 2ZL
      • London, United Kingdom, SE5 8BB
      • Manchester, United Kingdom, M13 9WU
        • Recruiting
        • Saint Mary's Hospital Manchester, Manchester University NHS Foundation Trust
        • Contact:
      • Port Talbot, United Kingdom, SA12 7BR
    • Newcastle upon Tyne
      • Newcastle, Newcastle upon Tyne, United Kingdom, NE3 3HD
        • Recruiting
        • The Newcastle upon Tyne Hospitals NHS Foundation Trust
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Fertility Healthcare Professionals' inclusion criteria are:

  • working at participating clinics; and
  • whose role involves a minimum of 10% of week time (half a day) SBN or being a non-clinical decision-maker (e.g., clinic/line managers).

Patients' inclusion criteria are

• adult individuals or couples attending participating clinics to discuss or undergo (in)fertility diagnosis or treatment with participating FHPs.

Exclusion criteria are:

  • not being able to read, speak or understand English;
  • not being able to provide consent.
  • for FHPs only, being unable to undergo the fertiShare training (e.g., visual impairments).

We will not be targeting groups or individuals deemed vulnerable. Potential participants are explicitly informed in the information sheet that, if they are worried about their mental health or psychological wellbeing they may chose not to participate at all. They are also advised to inform their fertility team and contact their GP in the usual way or the NHS Mental Health support service, www.nhs.yj/mental-health.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: fertiShare intervention
sharing bad news eLearning course

two-hour self-led eLearning course to support fertility staff in sharing bad news (SBN) with their patients

organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 offers SPIKES-based step-by-step guidance to ease SBNs. Module 3 offers guidance to cope with common challenges FHPs face: sharing bad news remotely, managing anger and uncertainty, and using good news to lessen the impact of bad news.

Each module offers video content-based lessons, case studies that illustrate guidance and brief quizzes for self-reflection and assessment. Case studies show learners optimal and suboptimal approaches to SBN.

Active Comparator: fertiShare control
basic communication training skills eLearning course

self-led eLearning course branded as fertiShare but designed to emulate the basic communication training healthcare providers receive as they undergo their professional degrees.

organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 introduces the communication cycle and associated communication techniques. Module 3 offers guidance regarding other basic communication skills: empathic communication, non-verbal communication, active listening and remote consultations, and communicating the likelihood of positive or negative treatment outcomes.

Each module offers video content-based lessons, case studies, and brief quizzes. All teaching elements remain at the basic level (remembering and understanding instead of analysing and applying).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Limited Efficacy Testing: changes from baseline in patients perceived FHPs' sharing bad news performance (primary outcome)
Time Frame: Within one week of enrolment in the study
Modified intention-to-treat (mITT, all FHPs randomized) and per protocol (PP, only FHPs who completed a sufficient dose) analyses of mean differences in patient reported FHPs' sharing bad news performance (primary outcome) between patients in the baseline (pre FHPs training) and follow-up (post FHPs training) cohort. Patient reported FHPs' sharing bad news performance will be assessed with an adapted version of the Sharing Bad News Behavioural Assessment Scale. The scale is composed of 23 items that list evidence-based best practice behaviours on how to share bad news (e.g., warn you they would be sharing bad news). Patients are asked to rate the degree to which the FHP did each behaviour on a Likert scale from 1- not at all to 5 - completely (or 6 - does not apply). A global average score is calculated that ranges from 1 to 5, with higher values indicating better sharing bad news performance.
Within one week of enrolment in the study

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Limited Efficacy Testing: changes from baseline in staff confidence in sharing bad news (secondary outcome)
Time Frame: From two weeks after enrolment to two weeks after training (fertiShare, control), which happens 5 months from enrolment
Modified intention-to-treat (mITT, all FHPs randomized) and per protocol (PP, only FHPs who completed a sufficient dose) analyses of changes in confidence in SBN (secondary outcome) from pre to post training with fertiShare or control eLearning. Confidence in sharing bad news will be assessed with an adapted version of the Breaking Bad News Assessment Scale. The scale is composed of 23 items that list evidence-based best practice behaviours on how to share bad news (e.g., warn patients you will be sharing bad news). FHPs are asked to rate how confident they feel doing each behaviour listed on a Likert scale from 1- not at all to 5 - completely (or 6 - does not apply). A global average score is calculated that ranges from 1 to 5, with higher values indicating higher confidence in sharing bad news.
From two weeks after enrolment to two weeks after training (fertiShare, control), which happens 5 months from enrolment
Limited Efficacy Testing: mean difference in patient trust in their Fertility Healthcare Professional (FHP) between the baseline and follow-up patient cohorts (secondary outcome)
Time Frame: Within one week of enrolment in the study
Modified intention-to-treat (mITT, all FHPs randomized) and per protocol (PP, only FHPs who completed a sufficient dose) analyses of mean differences in patient trust in their FHP (secondary outcome) between patients in the baseline and follow-up cohort. Trust will be assessed with the Wake Forest Physician Trust Scale. The scale is composed of ten statements describing care provided (e.g., They will do whatever it takes to get you all the care you need.). Patients are asked to rate their level of agreement with each statement on a Likert scale from 1- strongly disagree to 5-strongly agree. Trust is measured by the sum of the 10 item scores (reverse-scored for negative items), ranging from 10 to 50, with a higher score indicating more trust.
Within one week of enrolment in the study
Limited Efficacy Testing: mean difference in patients' satisfaction with care at the clinic (secondary outcome) between the baseline and follow-up patient cohorts
Time Frame: Within one week of enrolment in the study
Modified intention-to-treat (mITT, all FHPs randomized) and per protocol (PP, only FHPs who completed a sufficient dose) analyses of mean differences in patient satisfaction with care at the clinic (secondary outcome) between patients in the baseline and follow-up cohort. Assessed with five questions used by the Human Fertility and Embryology Authority for patients to rate their satisfaction with care provided at UK based fertility clinics (e.g., To what extent did you feel you were treated with privacy and dignity?). Patients answer on a Likert scale from 1-never to 5-always (answer scale anchors vary with question), with higher values indicating higher satisfaction with care.
Within one week of enrolment in the study
Limited Efficacy Testing: mean difference in patients' satisfaction with shared decision-making support regarding continuing or stopping fertility treatment (secondary outcome) between the baseline and follow-up patient cohorts (secondary outcome)
Time Frame: Within one week of enrolment in the study
Modified intention-to-treat (mITT, all FHPs randomized) and per protocol (PP, only FHPs who completed a sufficient dose) analyses of mean differences in patient satisfaction with shared decision-making support about continuing fertility treatment (secondary outcome) between patients in the baseline and follow-up cohort. Assessed with the Decisional Conflict Scale. Patients are asked to select which treatment option they prefer (doing another treatment cycle at clinic, doing another treatment cycle at a different clinic, stopping fertility treatment, other) and to rate the degree to which they agree with a list of 16 statements related to their decision (e.g., I know which options are available to me) on a Likert scale from 0-strongly agree to 4-strongly disagree. Total decisional conflict and sub-dimension scores (uncertainty, informed, values clarity, support) are calculated and linearly transformed to range from 0 to 100, with higher scores indicating more of the construct.
Within one week of enrolment in the study
Limited Efficacy Testing: mean difference in patients' uptake of and time to another stimulated In Vitro Fertilisation Cycle between the baseline and follow-up patients cohorts (secondary outcome)
Time Frame: 6 months and 2 weeks after enrolment
Modified intention-to-treat (mITT, all staff randomized) and per protocol (PP, only staff who completed a sufficient dose) analysis of mean differences in patient uptake of (yes, no, not recommended) and time to another stimulated IVF cycle (in days, not applicable) between patients in the baseline and follow-up cohort: data obtained via patient record review.
6 months and 2 weeks after enrolment

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Demand of intervention: Fertility Healthcare Professionals demand for intervention
Time Frame: Within two weeks after exposure (fertiShare, control training), which happens 5 months from enrolment
Number of Fertility Healthcare Professionals who registered with the eLearning and completed each lesson. module, and quiz
Within two weeks after exposure (fertiShare, control training), which happens 5 months from enrolment
Demand for intervention: Profile of Fertility Healthcare Processionals who registered and completed the intervention
Time Frame: Within two weeks after exposure (fertiShare, control training), which happens 5 months from enrolment
Demographic and professional profile of FHPs who registered and completed the intervention (fertiShare, control training)
Within two weeks after exposure (fertiShare, control training), which happens 5 months from enrolment
Acceptability of intervention: Fertility Healthcare Professionals experience of doing intervention
Time Frame: Within two weeks after exposure (fertiShare, control training), which happens at 5 months from enrolment
Quantitative ratings regarding 5 items describing the experience of doing the eLearning (e.g., I benefited, I learned). FHPs answer on a Likert-type scale ranging from 1 (not at all) to 5 (an extreme amount), presented in the eLearning evaluation form. Higher scores indicate higher acceptability of intervention.
Within two weeks after exposure (fertiShare, control training), which happens at 5 months from enrolment
Acceptability of intervention: Proportion of Fertility Healthcare Professionals recommending the intervention to colleagues
Time Frame: Within two weeks after exposure (fertiShare, control training), which happens at 5 months from enrolment
Proportion of staff reporting they recommend fertiShare to other colleagues in their situation, fertiShare improved their preparation to have difficult conversations with their patients, and fertiShare reduced their anxiety when having difficult conversations with their patients: post-exposure (fertiShare, control training) staff assessment
Within two weeks after exposure (fertiShare, control training), which happens at 5 months from enrolment
Acceptability of intervention: patients' satisfaction with how their Fertility Healthcare Professional shared bad news with them
Time Frame: Within one week of enrolment in the study
Patient self-reported satisfaction with how their FHP shared the bad news with them. Assessed with a single question "Overall, how satisfied are you with the way [name of participating staff member] shared or discussed with you the news that the IVF cycle was unsuccessful?", with a Likert-type response scale ranging from 1 (very dissatisfied) to 5 (very satisfied), presented in the patient pre- and post-cohorts' assessments
Within one week of enrolment in the study
Acceptability of intervention: process evaluation interviews with Fertility Healthcare Professionals and patients
Time Frame: Within one to three months after exposure, which happens six to eight months after enrolment for FHPs and one month after for patients
Open ended questions included in semi-structured process evaluation interviews with staff (e.g., Which aspects of FertiShare were particularly useful, if any?) and patients (e.g., What are your views about how staff shared with you the news that the IVF cycle was unsuccessful?)
Within one to three months after exposure, which happens six to eight months after enrolment for FHPs and one month after for patients
Implementation of intervention: Number of Fertility Healthcare Professionals who completed all intervention (fertiShare, control training) Modules and completed Module 1 and 2 only during the 4-week training period
Time Frame: Within two weeks after exposure (fertiShare, control training), which happens at 5 months from enrolment
Number of Fertility Healthcare Professionals who completed all intervention (fertiShare, control training) Modules (i.e., used intervention as intended) and completed Module 1 and 2 only (i.e., completed sufficient dose) during the 4-week training period: data stored by the eLearning
Within two weeks after exposure (fertiShare, control training), which happens at 5 months from enrolment
Implementation of intervention: process evaluation interviews with Fertility Healthcare Professionals and patients
Time Frame: Within one to three months after exposure, which happens six to eight months after enrolment for FHPs and one month after for patients
Open ended questions included in semi-structured process evaluation interviews with FHPs (e.g., Can you describe any changes you made in the way you SBN with your patients (if any) because of doing the fertiShare eLearning and why?) and patients (e.g., Can you think of any factors that made it harder or easier for staff to share the news with you in a sensitive way?)
Within one to three months after exposure, which happens six to eight months after enrolment for FHPs and one month after for patients
Practicality of intervention: Technical issues experienced by Fertility Healthcare Professionals
Time Frame: Within two weeks after exposure (fertiShare, control training), which happens at 5 months from enrolment
Fertility Healthcare Professionals' answers to multiple choice question (yes, no) about experiencing technical issues during the intervention (fertiShare, control training), presented in the intervention Evaluation form
Within two weeks after exposure (fertiShare, control training), which happens at 5 months from enrolment
Practicality of intervention: process evaluation interviews with Fertility Healthcare Professionals and patients
Time Frame: Within one to three months after exposure, which happens six to eight months after enrolment for FHPs and one month after for patients
Open ended questions included in semi-structured process evaluation interviews with FHPs (e.g., Where there any factors that made it easier or harder for you to do fertiShare?) and patients (e.g., Can you think of any factors that made it harder or easier for staff to share the news with you in a sensitive way?)
Within one to three months after exposure, which happens six to eight months after enrolment for FHPs and one month after for patients
Demand of study protocol - Participation
Time Frame: Participation assessed at enrolment
FHPs' and patients' participation (proportion of invited FHPs and patients who consent to participate) rates
Participation assessed at enrolment
Demand of study protocol - Retention
Time Frame: Retention assessment happens from 2 weeks to 5 months from enrolment for FHPs and within 2 weeks of enrolment for patients
FHPs' and patients' retention rates (proportion of FHPs and patients who fill each assessment).
Retention assessment happens from 2 weeks to 5 months from enrolment for FHPs and within 2 weeks of enrolment for patients
Acceptability of study protocol - Patients
Time Frame: Within two weeks of enrolment
Proportion of patients in the pre- and post-training cohorts who complete their respective online assessments
Within two weeks of enrolment
Acceptability of study protocol - Fertility Healthcare Professionals
Time Frame: Within two weeks from enrolment and within two weeks after exposure, which happens 5 months from enrolment
Proportion of FHPs who completed background and professional form, and pre- and post- exposure (fertiShare, control training) assessments
Within two weeks from enrolment and within two weeks after exposure, which happens 5 months from enrolment
Implementation of study protocol
Time Frame: Fertility Healthcare Professionals: from enrolment until end of participation (seven months from enrolment). Patients: from enrolment until end of participation (within 2 weeks of enrolment).
Issues reported by FHPs and patients to research team relating to study procedures or materials and reasons for non-participation/withdrawal from the study
Fertility Healthcare Professionals: from enrolment until end of participation (seven months from enrolment). Patients: from enrolment until end of participation (within 2 weeks of enrolment).
Practicality of study protocol - Fertility Healthcare Professionals and Patients
Time Frame: Fertility Healthcare Professionals: At enrolment, within five, six and seven months of enrolment. Patients: At enrolment, within two weeks and two months of enrolment.
Time taken by FHPs and patients to complete assessments and process evaluation interview
Fertility Healthcare Professionals: At enrolment, within five, six and seven months of enrolment. Patients: At enrolment, within two weeks and two months of enrolment.
All dimensions - Process Evaluation Interviews
Time Frame: Fertility Healthcare Professionals: Withing 7 months of enrolment. Patients: within 2 months of enrolment.
Open-ended questions included in semi-structured process evaluation interviews with FHPs and patients about the study methods (e.g., 'How demanding was participation in this study?' and, for staff only, 'How did you find the randomization process?')
Fertility Healthcare Professionals: Withing 7 months of enrolment. Patients: within 2 months of enrolment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sofia Gameiro, PhD, Cardiff University
  • Study Chair: Helen Falconer, Cardiff University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 8, 2024

Primary Completion (Estimated)

September 30, 2025

Study Completion (Estimated)

February 28, 2026

Study Registration Dates

First Submitted

August 29, 2024

First Submitted That Met QC Criteria

September 5, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Actual)

July 29, 2025

Last Update Submitted That Met QC Criteria

July 24, 2025

Last Verified

December 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SPON1955-23

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The study protocol will be submitted for publication. We will make the study data open on the Open Science Framework (with the participants' consent). This is an academic resource that makes data available for secondary analysis by other researchers and provides assurance of for science integrity and reproducibility.

IPD Sharing Time Frame

Start date: 01.01.2026, no end date.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infertility Assisted Reproductive Technology

Subscribe